Trial Profile
A phase I study of NBI-640756 for the treatment of essential tremor.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Sep 2016
Price :
$35
*
At a glance
- Drugs NBI 640756 (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Pharmacokinetics
- 03 Aug 2016 According to a Neurocrine Biosciences media release, status changed from active, no longer recruiting to completed.
- 05 May 2016 According to a Neurocrine Biosciences media release, data from this trial are expected in the second quarter of 2016.
- 05 May 2016 According to a Neurocrine Biosciences media release, the company has completed dosing in this trial.